| 摘要 |
1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering of 2 to 12 mg of 5-[4-[2-(N-methyl-N- (2 pyridyl) amino) ethoxy]benzyl]thiazolidine-2,4-dione (Compound I) or pharmaceutically acceptable forms and a biguanide antihyperglycaemic agent, to a mammal in need thereof. 2. A method according to claim 1, wherein the biguanide antihyperglycaemic agent is metformin. 3. A method according to claim 1, wherein the biguanide antihyperglycaemic agent is metformin hydrochloride. 4. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl]thiazolidine- 2,4-dione (Compound I) or pharmaceutically acceptable forms, metformin or pharmaceutically acceptable forms to a mammal in need thereof. 5. A method according to claim 1, wherein the metformin is metformin hydrochloride. 6. A method according to any one of claims 1 to 5, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I). 7. A method according to any one of claims 1 to 6, which comprises the administration of 2 to 4mg of Compound (I). 8. A method according to any one of claims 1 to 6, which comprises the administration of 4 to 8mg of Compound (I). 9. A method according to any one of claims 1 to 6, which comprises the administration of 8 to 12 mg of Compound (I). 10. A method according to any one of claims 1 to 6, which comprises the administration of 2 mg of Compound (I). 11. A method according to any one of claims 1 to 6, which comprises the administration of 4 mg of Compound (I). 12. A method according to any one of claims 1 to 6, which comprises the administration of 8 mg of Compound (I). 13. A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus, which method comprises an effective non-toxic and pharmaceutically acceptable amount of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl]thiazolidine- 2,4-dione (Compound I), biguanide antihyperglycaemic agent or pharmaceutically acceptable carrier therefor. 14. A composition according to claim 13, wherein the biguanide antihyperglycaemic agent is metformin. 15. A composition according to claim 13, wherein the biguanide antihyperglycaemic agent is metformin hydrochloride. 16. A composition according to any one of claims 13 to 15, which comprises 500mg or 850mg of metformin. 17. A composition according to any one of claims 13 to 16, wherein the, which comprises 2 to 12 mg of Compound (I). 18. A pharmaceutical composition comprising an 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl]thiazolidine- 2,4-dione (Compound I), a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor, for use as an active therapeutic substance. 19. A use of pharmaceutical composition comprising an 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy] benzyl]thiazolidine- 2,4-dione (Compound I), a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor, for use in the treatment of diabetes mellitus and conditions associated with diabetes mellitus.
|
